Contributors

S. Jay Olshansky, a professor at the University of Illinois at Chicago's School of Public Health, is an author of The Quest for Immortality: Science at the Frontiers of Aging. He, Daniel Perry, executive director of the Alliance for Aging Research, Richard Miller, professor of pathology at University of Michigan, Ann Arbor, and Robert Butler, founding director of the National Institute on Aging, call for an extension of healthy life in In Pursuit of the Longevity Dividend. "We're

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

S. Jay Olshansky, a professor at the University of Illinois at Chicago's School of Public Health, is an author of The Quest for Immortality: Science at the Frontiers of Aging. He, Daniel Perry, executive director of the Alliance for Aging Research, Richard Miller, professor of pathology at University of Michigan, Ann Arbor, and Robert Butler, founding director of the National Institute on Aging, call for an extension of healthy life in In Pursuit of the Longevity Dividend. "We're not proposing that we should live for 500 years, or 1,000 years, or become immortal," says Olshansky. "We're proposing a modest but achievable sevenyear delay."

Marc Vidal, director of the Center for Cancer Systems Biology at the Dana Farber Cancer Institute, describes his and colleagues' efforts to create a "serious map" of the human interactome, "a complete set of macromolecular interactions in the cell," in Time for a Human Interactome Project?. He ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies